This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
homes had to have at least 100 residents and have no stated policies for pneumonia treatment. Two nursing homes withdrew from the study after randomisation but before any patients had been included. A total of 680 patients were included in the study, of whom 327 were in nursing homes allocated to the clinical pathway and 353 were in nursing homes providing usual care.
Study design
The study was a cluster, randomised controlled trial. An independent statistician performed the randomisation using random-number tables. Blinding to the treatment group was not feasible in this study. The patients were followed up for 4 weeks. Data on 661 (97%) patients, 314 in the clinical pathway group and 347 in the usual care group, were obtained. Fourteen patients withdrew from the study (9 in the clinical pathway group and 5 in the usual care group), three were transferred from their nursing home (2 in the clinical pathway group and 1 in the usual care group), and two in the clinical pathway group were excluded because of adverse reactions.
Analysis of effectiveness
The primary health outcomes used were: The analysis was conducted on an intention to treat basis. The two patient groups appear to have been comparable in terms of their age, gender, co-morbidities and severity of illness.
Effectiveness results
The hospitalisation rate was 8% with a mean of 0.79 days per patient in the clinical pathway group, compared with 20% with a mean of 1.74 days per patient in the usual care group. The difference was 12% (95% confidence interval, CI: 5 to 18; p=0.001) for the hospitalisation rate and 0.94 days (95% CI: 0.34 to 1.55; p=0.004) for the mean days in hospital per patient.
The mortality rate was 3.1% in the clinical pathway group versus 6.0% in the usual care group, (p=0.23).
The fall rate was 10.9% in the clinical pathway group versus 9.5% in the usual care group, (p=0.60).
The change in quality of life was -0.032 in the clinical pathway group versus -0.037 in the usual care group, (p=0.055).
The change in functional status was -0.105 in the clinical pathway group versus -0.175 in the usual care group, (p=0.23).
Normalisation of vital signs took a mean of 2.55 days in the clinical pathway group and 2.66 days in the usual care
Synthesis of costs and benefits
Not relevant since, in effect, a cost-consequences analysis was performed.
Authors' conclusions
"A clinical pathway for treating residents of nursing homes with pneumonia and other lower respiratory tract infections results in similar clinical outcomes to usual care, reduces hospitalisations, and results in an overall reduction of health care costs."
CRD COMMENTARY -Selection of comparators
In this study, the treatment of pneumonia by a nurse-led clinical pathway was compared with treatment by the patient's physician. The latter (treatment by the patient's physician) represented usual care in the authors' setting. You should consider how this compares with usual care in your own setting prior to applying the results of this study.
Validity of estimate of measure of effectiveness
The clinical effectiveness data were taken from a clustered, randomised controlled trial, which was appropriate for the study question. The study sample was restricted to nursing homes that had at least 100 beds and the authors acknowledged that this might limit the generalisability of the study findings. Sample size calculations that took account of the clustered nature of the trial were undertaken in the planning phase of the study, and the sample was of sufficient size. The method of randomisation, study length, and loss to follow-up were reported, and these suggest that the internal validity of the study is likely to be good. It was not practical to blind either the patients or the health care staff to the treatment group allocation. Statistical analysis of the trial data was appropriate and took account of the clustering in the trial.
Validity of estimate of measure of benefit
No summary measure of health benefit was used in the economic analysis. In effect, a cost-consequences analysis was performed.
Validity of estimate of costs
The economic perspective of the study was that of the third-party health care payer and all appropriate costs appear to have been included. A breakdown of resource use and costs was provided for both treatment groups. This enhances the generalisability of the study findings. However, although the degree of uncertainty around the total cost data was described using confidence intervals, no statistical or sensitivity analyses were undertaken. Charges were used to proxy price which, given the third-party payer perspective, was appropriate. A clear price year was reported, which will permit future reflation exercises. Discounting was not performed but was not necessary given the short follow-up period.
